BackgroundNosocomial infections are one of the main causes of mortality and morbidity in hospitals, especially in intensive care units (ICUs).ObjectiveThe aim of this study was to examine the impact of garlic tablets on nosocomial infections in hospitalized patients in intensive care units.MethodsThis clinical trial was carried out on 94 patients, admitted to the intensive care units in Kashani and Al-Zahra hospitals from January 21, 2014 to December 20, 2014. Firstly, the patients were randomly selected by simple sampling, then they were assigned into case and control groups. The case group administered one 400 mg garlic tablet daily for 6 days and the control group received placebo. During the study, inflammatory blood factors and infection occurrence in the two groups were compared. The Data were analyzed by SPSS software version 22 through descriptive tests such as independent t-test, Chi-square test, ANOVA and exact Fisher test for the analyses of primary and secondary outcomes.ResultsDuring the study period, 78 cases of intravenous catheter tip were sent to laboratory for culture, of which, 37 cases were in the intervention group and 41 in the control group. Culture results of Catheter tips was positive in 5 cases and all five cases were in the control group. Frequency distribution of catheter tip culture was significantly higher in the control group than that of the intervention group (p=0.03).ConclusionBased on the results of our study, in people with weakened immune systems and in people with high incidence of opportunistic infections, it is necessary to strengthen their body’s immune system stimulants before dealing with these infectious agents, and cause decrease in the diseases insusceptible people. It was suggested that garlic supplementation has shown to be effective in patients admitted to ICU, who are highly susceptible to nosocomial infection, and it can be used for the prevention of septicemia and urinary tract infections. However, further research with larger sample size is needed.Trial registrationThe trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: IRCT207406156480N6.FundingShahrekord University of Medical Sciences financially supported this research.

Background and aims: Acute respiratory distress syndrome (ARDS) treatment is supportive, and there is no currently approved treatment for it. This study, therefore, aimed to investigate the effect of endotracheal administration of N-acetyl cysteine (NAC) and heparin on the level of secretion and partial thromboplastin time (PTT) in ARDS patients under mechanical ventilation. Methods: In this clinical trial study, 70 patients aged over 18 years (30 women and 40 men) admitted to the intensive care unit were randomly selected following the allocation rule and then divided into two groups (intervention and control). In addition to the routine and available treatments in the ward given to the patients in both groups, the control group also received 10 mL of normal saline every six hours through the endotracheal route, while the intervention group received 500 units of heparin plus 200 mg of NAC dissolved in 10 mL of normal saline every six hours through the same administration route. Results: The mean and standard deviation levels of PTT in the control and intervention groups were 30.3743 ± 7.78008 and 32.2286 ± 8.31047, respectively, with no significant difference (P>0.05); the volume of secretion on days 1-3 was not significantly different between the two groups, but the difference was statistically significant from day 4 onwards (P<0.05). Conclusion: Taking the combination of NAC and heparin through the endotracheal route was effective in reducing pulmonary secretion, and may have been considered a considerable positive step in providing patients suffering from acute respiratory failure and under mechanical ventilation with supportive care. However, it is recommended that further clinical studies be conducted before arriving at any definitive conclusion.

BACKGROUND Although stenting for the treatment of large and multiple common bile duct stones has been acceptable to everyone, its efficacy and outcome have not been studied in comparison with other endoscopic procedures. The purpose of this study was to compare the consequences of stenting and endoscopic papilla balloon dilatation for the treatment of large and multiple common bile duct stones. METHODS In a double-blind clinical trial, of 431 patients with bile duct stones referred to the treatment center, 64 patients with multiple common bile duct stones ( ≥ 3) and more than 15 cm were selected for the study, then by random allocation rule the participants were allocated in two groups. They were entered into two different endoscopic papillary balloon dilatation (EPBD) and common bile ducts stenting treatments so that both procedures were performed by a person. Both groups were assessed from the point of views therapeutic outcomes such as duct cleaning, pancreatitis, isolated pain, and duct rupture. Data were collected by a self-made questionnaire that was used before and after the procedure to obtain the needed information. Then data were analyzed using SPSS software version 22 and descriptive and analytical tests were used as appropriated. RESULTS Although the duct cleaning and the complete removal of the stones in the stenting treatment procedure was 93.8%, and in EPBD was 78.3%, no significant difference was observed between the two groups (p = 0.14). Pancreatitis significantly increased after the first and second endoscopic retrograde cholangiopancreatography (ERCP) in the stent group compared with EPBD (p = 0.02). Also, the most frequent cases of isolated pain were in the endoscopic group EPBD (p = 0.0). However, the occurrence of perforation after first ERCP and EPBD was zero, but in the second stage of ERCP, 3.3% of the patients had perforations (p = 0.99). The results indicated that the shape of the stone (circular and angled) was not effective in the result of treatment in the two groups. CONCLUSION The results of this study indicated that in case of experience and skill in conducting the ERCP, common bile duct stenting is still the first line of treatment for large and multiple stones of the common bile ducts.